NLS Pharmaceutics AG (NLSP)
NASDAQ: NLSP · Real-Time Price · USD
2.200
-0.020 (-0.90%)
At close: Aug 28, 2025, 4:00 PM
2.180
-0.020 (-0.91%)
After-hours: Aug 28, 2025, 7:45 PM EDT
NLS Pharmaceutics AG Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for NLS Pharmaceutics AG.
Price Target: $ (0.00%)
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for NLS Pharmaceutics AG.
Recommendation Trends
| Rating | Apr '23 | May '23 | Jun '23 | Jul '23 | Aug '23 | Sep '23 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Sep 14, 2023 |
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $160 | Hold → Strong Buy | Upgrades | $160 | +7,172.73% | Dec 8, 2022 |
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 8, 2022 |
| Laidlaw & Co. | Laidlaw & Co. | Strong Buy Initiates $240 | Strong Buy | Initiates | $240 | +10,809.09% | Sep 6, 2022 |
| Brookline Capital | Brookline Capital | Strong Buy Initiates $480 | Strong Buy | Initiates | $480 | +21,718.18% | Mar 12, 2021 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.46
from -2.63
EPS Next Year
n/a
from -0.46
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 |
|---|---|
| High | n/a |
| Avg | n/a |
| Low | n/a |
Revenue Growth
| Revenue Growth | 2025 |
|---|---|
| High | - |
| Avg | - |
| Low | - |
EPS Forecast
| EPS | 2025 |
|---|---|
| High | -0.47 |
| Avg | -0.46 |
| Low | -0.44 |
EPS Growth
| EPS Growth | 2025 |
|---|---|
| High | - |
| Avg | - |
| Low | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.